Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heterologous Prime-Boost with MVC-COV1901 after mRNA-1273
NCT05079633Phase 4Completed
- Sponsor
- National Taiwan University Hospital
- Start
- Sep 2021
- Primary completion
- Oct 2021
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 4 trial of MVC-COV1901 in coronavirus disease 2019 (COVID-19), sponsored by National Taiwan University Hospital. Started Sep 2021; status: completed.
02
Drugs
MVC-COV1901
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05079633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05079633.